NASDAQ:COGT Cogent Biosciences Q3 2026 Earnings Results & Report $31.65 0.00 (0.00%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$31.72 +0.07 (+0.22%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cogent Biosciences missed analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.59 versus the -$0.5573 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeBefore Market OpensConference Call DateNovember 5, 2026Conference Call12:30 PM ET Cogent Biosciences EPS ResultsActual EPS-$0.59Consensus EPS -$0.5573Beat/MissMissed by -$0.0327One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCogent Biosciences Revenue ResultsActual RevenueN/AExpected Revenue$7.21 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cogent Biosciences Q3 2026 Earnings FAQ Did Cogent Biosciences beat earnings estimates for Q3 2026? Cogent Biosciences (NASDAQ:COGT) reported earnings of -$0.59 per share for Q3 2026, missing the consensus estimate of -$0.5573. The report was announced on Monday, November 9, 2026. Cogent Biosciences Earnings HeadlinesCogent Biosciences (COGT) Faces A Valuation Test As FDA Decisions Draw CloserNovember 6 at 7:28 AM | finance.yahoo.comCogent Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 9 at 1:00 AM | Profits Run (Ad)Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsNovember 5, 2026 | finance.yahoo.comCogent Biosciences (COGT) Projected to Post Quarterly Earnings on FridayOctober 30, 2026 | americanbankingnews.comCogent Biosciences to Participate in the Guggenheim Healthcare Innovation ConferenceOctober 27, 2026 | globenewswire.comSee More Cogent Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email. Email Address About Cogent BiosciencesCogent Biosciences (NASDAQ:COGT) is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role. Bezuclastinib is investigational and has not been established as a treatment for these diseases. Cogent took its current name in 2020 following a merger with Unum Therapeutics. The company’s activities center on developing and advancing its precision-medicine pipeline through clinical research.View Cogent Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?The Ugly Truth Behind SoundHound’s Q3 ResultsSandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater? Upcoming Earnings Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
